Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations

doi:10.3748/wjg.v28.i39.5691

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 39

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5836)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

432

WORD

HTML

3475

Figures (1-1)

357

Tables (1-1)

274

Sum=4595

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

153

Download

257

Sum=410

Publishing Process of This Article

Item

Count

Browse

261

Download

570

Sum=831

Oct 21, 2022 (publication date) through May 10, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 21, 2022; 28(39): 5691-5706
Published online Oct 21, 2022. doi: 10.3748/wjg.v28.i39.5691

Open in New Tab Full Size Figure Download Figure

Figure 1 Common pathophysiologic mechanisms in metabolic dysfunction-associated fatty liver disease and chronic kidney disease. FXR: Farnesoid X receptor; MAFLD: Metabolic dysfunction-associated fatty liver disease; SCFA: Short-chain fatty acid; TMAO: Trimethylamine N-oxide.

Citation: Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706
URL: https://www.wjgnet.com/1007-9327/full/v28/i39/5691.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i39.5691